HM43239 for AML

Contact a Trial Coordinator for more information on our trials

Contact Us

Trial Summary

Recruiting

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Condition

Acute Myeloid Leukemia

Actual Start Date

March 11, 2019

Estimated Primary Completion Date

January 2023

Detailed Info

Brief Summary

This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety,

tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of HM43239

monotherapy in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).

Study Phase

Phase 1/Phase 2

Estimated Enrollment

120

Estimated Primary Completion Date

January 2023

Study Type

Interventional

Interventions

  • Drug: HM43239

Sponsor

Aptose Biosciences Inc.

Locations

The following cities have HM43239 clinical trial sites. Please check back often as locations will be updated.

Enrollment

For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov

The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.